Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks - Quiz - MDSpire

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • By

  • Howard L. Sofen

  • Ranga Gogineni

  • Tushar Nishandar

  • Jerry Bagel

  • May 9, 2026

Share

Original Source(s)

Related Content